

Novo Nordisk announces decision to discontinue Levemir[®] (insulin detemir)

- [Novo Nordisk recently announced](#) the discontinuation of [Levemir \(insulin detemir\)](#) due to business reasons. The discontinuation is not due to any safety or efficacy issues.
- Supply disruptions of Levemir FlexPen[®] are expected in mid-January 2024. Levemir FlexPen will be discontinued on April 1, 2024. Levemir vial will be discontinued on December 31, 2024.
- Levemir is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
- Other long-acting insulins such as insulin glargine [e.g. [Basaglar[®] \(insulin glargine\)](#), [insulin glargine \(insulin glargine yfgn\)](#), [Toujeo[®] \(insulin glargine\)](#)] and [Tresiba[®] \(insulin degludec\)](#) are currently available.
- Contact the Novo Nordisk Customer Care Center at **1-800-727-6500** for any questions related to this discontinuation.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.